STK11 and metabolic disease: Progress in understanding the role of microbiota as a helper in the treatment of metabolic disorders has also been delivered by the team of Hua et al., who showed that a newly formed compound—P7C3-A20—has the ability to increase levels of NAD+ and alleviated NAFLD through promoting fibroblast growth factors (FGF) 1 and 21 in an LKB1/AMPK/CRTC2-conditional manner, leading to the growth and a re-balancing of gut microbiota [31].